The U.S. clinical research landscape faces uncertainty. NIH grant cancellations, FDA staffing cuts, and regulatory uncertainty are creating real challenges for the industry’s traditional leader. Europe has an opportunity if it acts decisively.
In his latest op-ed for BioSpace, Craig Koch examines why this moment matters for European clinical research. While the EEA’s share of global trials dropped from 22% to just 12% over the past decade, current U.S. instability could change that trajectory.
From policy reforms and public-private partnerships to new investments in R&D infrastructure, the groundwork is being laid. But with challenges like regulatory fragmentation and looming tariffs, Europe must act swiftly and strategically.
Craig’s take: “Political shifts within the U.S. present an opportunity for Europe to attract a sizable chunk of U.S. life science expertise and investment. But its success is by no means assured; to capitalize on this moment and assume clinical trial leadership, Europe must play its cards right.”
Read Craig’s full analysis here: https://www.biospace.com/drug-development/opinion-u-s-uncertainty-creates-clinical-trial-leadership-opportunity-for-europe
